<DOC>
	<DOCNO>NCT03000218</DOCNO>
	<brief_summary>A clinical study evaluate pharmacokinetics , metabolomics biomarker subject overweight liver problem ursodeoxycholic acid multiple administration</brief_summary>
	<brief_title>Evaluation PK Biomarkers After UDCA Administrations Subjects Who Are Overweight Have Liver Problems</brief_title>
	<detailed_description>This study randomize , open-label , three-treatment , one-sequence , placebo-controlled , multiple drug administration design . The purpose study follow ; To evaluate pharmacokinetics , metabolomics biomarker subject overweight liver problem ursodeoxycholic acid administration</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Healthy Subjects age 18 50 year A body mass index ( BMI ) range 25.0 kg/m2 30.0 kg/m2 . A alanine aminotransferase ( ALT ) range 40 200 IU/L Good health base complete medical history , physical examination , vital sign , electrocardiography ( ECG ) , clinical laboratory evaluation . Subjects clinically significant disease cardiovascular , respiratory , renal , endocrinological , hematological , gastrointestinal , neurological ( central nervous system ) , psychiatric disorder malignant tumor Subject judge eligible study participation investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>